Rheumatoid Arthritis


US FDA red light for Janssen’s arthritis mAb

By Flora Southey

The US FDA has rejected Janssen Biotech’s application for sirukumab, a monoclonal antibody (mAb) designed to treat severely active rheumatoid arthritis (RA). 


Mundipharma releases 2-year Remsima efficacy data

By Gareth Macdonald

Mundipharma has begun the latest phase of its Remsima promotion campaign, unveiling two-year data indicating the infliximab biosimilar is as safe and effective as the originator.